The moral and fiscal implications of antiretroviral therapies for HIV in Africa by Paul Collier and Olivier Sterck
By: Collier, Paul
.
Contributor(s): Sterck, Olivier
.
Material type: 





Item type | Current location | Home library | Call number | Status | Date due | Barcode |
---|---|---|---|---|---|---|
Artículos | IEF | IEF | OP 286/2018/2-2 (Browse shelf) | Available | OP 286/2018/2-2 |
Browsing IEF Shelves Close shelf browser
No cover image available | No cover image available | No cover image available | No cover image available | No cover image available | No cover image available | No cover image available | ||
OP 286/2018/1-3 Information transmission within federal fiscal architectures | OP 286/2018/2 Oxford Economic Papers | OP 286/2018/2-1 Top incomes and inequality in the UK | OP 286/2018/2-2 The moral and fiscal implications of antiretroviral therapies for HIV in Africa | OP 286/2018/2-3 Fiscal consolidation after the Great Recession | OP 286/2018/3 Oxford Economic Papers | OP 286/2018/4 Oxford Economic Papers |
Disponible en formato electrónico a través de la Biblioteca del IEF.
Resumen.
Bibliografía.
Thanks to antiretroviral therapies (ART), people living with HIV (PLHIV) can now have a near-normal life at a cost of a few hundred dollars per year. We postulate that given this new low cost of maintaining lives, there is a moral duty to rescue
those who are infected. This obligation creates a financial quasi-liability which for some African countries is comparable to their debt-to-GDP ratios. We construct a model to show that expenditure on prevention can pre-empt some of these liabilities.
However, even with optimal prevention the quasi-liability is likely to remain too high to be affordable for a significant number of African countries. Extending the model to two players, we show that if the international community accepts part of the quasi-liability, as it does, it should finance a broadly equal share of prevention and treatment of future infections to mitigate moral hazard and avoid sub-optimal investment in prevention.
There are no comments for this item.